Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Viriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral Formulation
SAN DIEGO, Dec.
Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
PARIS and San Diego, California – December 9, 2019 – Sanofi and Synthorx, Inc.
A step toward an Alzheimer's treatment? New ultrasound can cuts through the blood-brain barrier to target dementia-linked plaques
Scientists have taken a step toward treating Alzheimer's by gaining access to hard-to-reach areas of the brain that they believe drugs to repair the disease's damage need to target, a new stud...
Scientists discover molecule that destroys pancreatic cancer cells
A little molecule named PJ34 can cause cancer cells to self-destruct, according to an Israeli study published recently in the biomedical journal Oncotarget.
Study: Aspirin anti-cancer
A study conducted by the US National Institutes of Health showed that small doses of aspirin may increase the chances of overcoming cancer.
Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD
Bristol-Myers Squibb (BMS) has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its Orencia (abatacept) to prevent moderate to severe acut...
Diabetes drug has unexpected, broad implications for healthy aging
Metformin is the most commonly prescribed type 2 diabetes drug, yet scientists still do not fully know how it works to control blood sugar levels.
Acadia's Nuplazid could hit blockbuster heights after strong psychosis data: analyst
When Acadia trumpeted news that it would end a late-stage trial for its Nuplazid in dementia-related psychosis (DRP) early, it represented a big win for a drugmaker still stinging from a major...
Astellas inks $3B Audentes buyout to expand in gene therapy
Astellas Pharma is set to buy Audentes Therapeutics for $3 billion.
Ardelyx drug reduces elevated phosphate levels, late-stage study shows
(Reuters) - Ardelyx Inc’s experimental drug has shown promise in a late-stage study as a standalone therapy to reduce elevated blood phosphate levels in patients with chronic kidney disease ...
World first as artificial neurons developed to cure chronic diseases
Artificial neurons on silicon chips that behave just like the real thing have been invented by scientists – a first-of-its-kind achievement with enormous scope for medical devices to cure chronic di...
NICE approves breast cancer treatment through Cancer Drugs Fund
NICE has approved palbociclib through the Cancer Drugs Fund, meaning that women with advanced breast cancer who have already received hormone therapy will now be eligible for palbociclib on the NHS.
339
340
341
342
343
344
345
346
347
